Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome

AIM: Wolfram Syndrome (WS) is a rare condition caused by mutations in Wfs1, with a poor prognosis and no cure. Mono-agonists targeting the incretin glucagon-like-peptide 1 (GLP-1) have demonstrated disease-modifying potential in pre-clinical and clinical settings. Dual agonists that target GLP-1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagomäe, Toomas, Gaur, Nayana, Seppa, Kadri, Reimets, Riin, Pastak, Marko, Plaas, Mihkel, Kaasik, Allen, Vasar, Eero, Plaas, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611518/
https://www.ncbi.nlm.nih.gov/pubmed/37900147
http://dx.doi.org/10.3389/fendo.2023.1234925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611518/
https://www.ncbi.nlm.nih.gov/pubmed/37900147
http://dx.doi.org/10.3389/fendo.2023.1234925

Ejemplares similares